StockData
AgomAb Therapeutics NV logo

AgomAb Therapeutics NV (AGMB) stock

AGMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 23, 2026Score 2/30
$5.92−0.05 (-0.84%)

Close on Nov 17, 2026Market cap $148.00KP/E –Yield –

AgomAb Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was €48.88M, up 24.3% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025€48.88M+24.3%
FY2024Dec 31, 2024€39.31M+49.4%
FY2023Dec 31, 2023€26.31M–

More AgomAb Therapeutics figures

See a number that looks wrong?